8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 2, 2026·SEC
Xeris Biopharma Holdings, Inc.(XERS)Earnings, Financials & Key Ratios
XERS•NASDAQ
2171.9× P/E·Price updated Jun 19, 2026
AboutXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Show more
- Revenue$292M+43.7%
- EBITDA$37M+276.3%
- Net Income$554K+101.0%
- EPS (Diluted)0.00+100.9%
- Gross Margin81.7%-0.2%
- EBITDA Margin12.7%+222.6%
- Operating Margin8.53%+151.5%
- Net Margin0.19%+100.7%
- ROE4.05%
XERS Key Insights
Xeris Biopharma Holdings, Inc. (XERS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 70.2%
✗Weaknesses
- ✗High debt to equity ratio of 2.8x
- ✗Shares diluted 17.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 87.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XERS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XERS Price & Volume
Xeris Biopharma Holdings, Inc. (XERS) stock price & volume — 10-year historical chart
Loading chart...
XERS Growth Metrics
Xeris Biopharma Holdings, Inc. (XERS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years70.2%
3 Years38.33%
TTM41.47%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM126.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM121.33%
Return on Capital
10 Years-52.33%
5 Years-24.05%
3 Years-7.53%
Last Year10.03%
XERS Recent Earnings
Xeris Biopharma Holdings, Inc. (XERS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.01+465.0%
$0.00
Rev
$82M+3.3%
$80M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.06+100.0%
$0.03
Rev
$86M+4.4%
$82M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.00-65.0%
$0.01
Rev
$74M-13.5%
$86M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.01+66.7%
$0.03
Rev
$72M-1.0%
$72M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.01vs $0.00+465.0% | $82Mvs $80M+3.3% |
| Q2 2026 | Mar 2, 2026 | $0.06vs $0.03+100.0% | $86Mvs $82M+4.4% |
| Q4 2025 | Nov 6, 2025 | $0.00vs $0.01-65.0% | $74Mvs $86M-13.5% |
| Q3 2025 | Aug 7, 2025 | $0.01vs $0.03+66.7% | $72Mvs $72M-1.0% |
Based on last 12 quarters of dataView full earnings history →
XERS Peer Comparison
Xeris Biopharma Holdings, Inc. (XERS) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 CORT | 8.58B | 79.91 | 97.45 | 12.79% | 6.23% | 7.5% | 0.01 | |
 AMRX | 5.1B | 16.21 | 73.68 | 8.05% | 2.39% | 7.47% | 0.13 | |
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare XERS vs Peers
Xeris Biopharma Holdings, Inc. (XERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XERS Income Statement
Xeris Biopharma Holdings, Inc. (XERS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.56M | 2.46M | 2.72M | 20.43M | 49.59M | 110.25M | 163.91M | 203.07M | 291.85M | 314.85M |
Revenue Growth % | 44.74% | 58.42% | 10.43% | 650.73% | 142.67% | 122.32% | 48.68% | 23.89% | 43.72% | 41.47% |
Cost of Goods Sold | 4K | 42K | 1.6M | 9.33M | 13.32M | 22.63M | 28.64M | 36.83M | 53.41M | 57.97M |
COGS % of Revenue | 0.26% | 1.7% | 58.89% | 45.65% | 26.86% | 20.53% | 17.48% | 18.14% | 18.3% | - |
Gross Profit | 1.55M▲ 0% | 2.42M▲ 56.1% | 1.12M▼ 53.8% | 11.11M▲ 892.6% | 36.27M▲ 226.6% | 87.61M▲ 141.5% | 135.27M▲ 54.4% | 166.24M▲ 22.9% | 238.43M▲ 43.4% | 256.88M▲ 0% |
Gross Margin % | 99.74% | 98.3% | 41.11% | 54.35% | 73.14% | 79.47% | 82.52% | 81.86% | 81.7% | 81.59% |
Gross Profit Growth % | 45.45% | 56.12% | -53.82% | 892.58% | 226.57% | 141.55% | 54.39% | 22.89% | 43.43% | - |
Operating Expenses | 28.18M | 61.77M | 123.5M | 94.65M | 151.43M | 169.55M | 179.28M | 199.88M | 213.54M | 220.98M |
OpEx % of Revenue | 1811.12% | 2505.76% | 4537.07% | 463.19% | 305.36% | 153.79% | 109.37% | 98.43% | 73.17% | - |
Selling, General & Admin | 8.02M | 21.11M | 63.06M | 73.73M | 125.72M | 137.75M | 146.09M | 163.48M | 182.37M | 191.5M |
SG&A % of Revenue | 515.1% | 856.51% | 2316.72% | 360.81% | 253.51% | 124.94% | 89.13% | 80.5% | 62.49% | - |
Research & Development | 20.17M | 40.65M | 60.44M | 20.92M | 25.16M | 20.97M | 22.34M | 25.56M | 31.16M | 32.2M |
R&D % of Revenue | 1296.02% | 1649.25% | 2220.35% | 102.38% | 50.74% | 19.02% | 13.63% | 12.59% | 10.68% | - |
Other Operating Expenses | -1K | 0 | 0 | 0 | 550K | 10.84M | 10.84M | 10.84M | 0 | 0 |
Operating Income | -26.63M▲ 0% | -59.34M▼ 122.9% | -122.38M▼ 106.2% | -83.55M▲ 31.7% | -115.16M▼ 37.8% | -81.94M▲ 28.8% | -44.01M▲ 46.3% | -33.65M▲ 23.5% | 24.9M▲ 174.0% | 35.9M▲ 0% |
Operating Margin % | -1711.38% | -2407.46% | -4495.96% | -408.84% | -232.22% | -74.32% | -26.85% | -16.57% | 8.53% | 11.4% |
Operating Income Growth % | -101.26% | -122.85% | -106.22% | 31.73% | -37.84% | 28.84% | 46.29% | 23.55% | 173.99% | - |
EBITDA | -26.45M | -59.02M | -121.3M | -82.08M | -113.28M | -69.27M | -30.85M | -21.02M | 37.05M | 48.51M |
EBITDA Margin % | -1700% | -2394.48% | -4456.36% | -401.66% | -228.43% | -62.83% | -18.82% | -10.35% | 12.7% | 15.41% |
EBITDA Growth % | -101.69% | -123.14% | -105.51% | 32.34% | -38.01% | 38.85% | 55.47% | 31.86% | 276.26% | 588.19% |
D&A (Non-Cash Add-back) | 177K | 320K | 1.08M | 1.47M | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M | 12.61M |
EBIT | -26.55M | -57.53M | -118.88M | -80.59M | -115.55M | -81.98M | -36.9M | -26.62M | 554K | 32.32M |
Net Interest Income | 122K | -932K | -4.35M | -2.9M | -6.87M | -11.52M | -21.86M | -27.85M | -24.34M | -23.89M |
Interest Income | 124K | 1.61M | 2.81M | 4.46M | 313K | 2.58M | 4.75M | 5.32M | 4.74M | 4.77M |
Interest Expense | 2K | 2.54M | 7.16M | 7.36M | 7.18M | 14.1M | 26.61M | 33.17M | 29.08M | 28.66M |
Other Income/Expense | 75K | -736K | -3.66M | -7.7M | -7.57M | -14.14M | -19.49M | -23.46M | -24.34M | -23.89M |
Pretax Income | -26.55M▲ 0% | -60.08M▼ 126.3% | -126.04M▼ 109.8% | -91.25M▲ 27.6% | -122.72M▼ 34.5% | -96.08M▲ 21.7% | -63.5M▲ 33.9% | -57.1M▲ 10.1% | 554K▲ 101.0% | 12.01M▲ 0% |
Pretax Margin % | -1706.56% | -2437.32% | -4630.35% | -446.54% | -247.48% | -87.15% | -38.74% | -28.12% | 0.19% | 3.81% |
Income Tax | 1K | 0 | -458K | -110K | 0 | -1.42M | -1.25M | -2.27M | 0 | 0 |
Effective Tax Rate % | -0% | 0% | 0.36% | 0.12% | 0% | 1.48% | 1.97% | 3.97% | 0% | 0% |
Net Income | -26.55M▲ 0% | -60.08M▼ 126.3% | -125.58M▼ 109.0% | -91.14M▲ 27.4% | -122.72M▼ 34.7% | -94.66M▲ 22.9% | -62.26M▲ 34.2% | -54.84M▲ 11.9% | 554K▲ 101.0% | 12.01M▲ 0% |
Net Margin % | -1706.56% | -2437.32% | -4613.52% | -446% | -247.48% | -85.86% | -37.98% | -27% | 0.19% | 3.81% |
Net Income Growth % | -101.03% | -126.26% | -109.02% | 27.42% | -34.66% | 22.87% | 34.23% | 11.92% | 101.01% | 126.64% |
Net Income (Continuing) | -26.55M | -60.08M | -125.58M | -91.14M | -122.72M | -94.66M | -62.26M | -54.84M | 554K | 12.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -13.09▲ 0% | -4.99▲ 61.9% | -3.49▲ 30.1% | -2.14▲ 38.7% | -1.55▲ 27.6% | -0.70▲ 54.8% | -0.45▲ 35.7% | -0.37▲ 17.8% | 0.00▲ 100.9% | 0.07▲ 0% |
EPS Growth % | -82.57% | 61.88% | 30.06% | 38.68% | 27.57% | 54.84% | 35.71% | 17.78% | 100.86% | 121.33% |
EPS (Basic) | -13.09 | -4.99 | -3.49 | -2.14 | -1.55 | -0.70 | -0.45 | -0.37 | 0.00 | - |
Diluted Shares Outstanding | 2.03M | 12.05M | 26.11M | 42.64M | 79.03M | 135.63M | 137.67M | 146.77M | 172.74M | 177.63M |
Basic Shares Outstanding | 2.03M | 12.05M | 26.11M | 42.64M | 79.03M | 135.63M | 137.67M | 146.77M | 160.43M | 170.52M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XERS Balance Sheet
Xeris Biopharma Holdings, Inc. (XERS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 44.05M | 117.9M | 87.48M | 152.21M | 142.6M | 186.82M | 156.26M | 167.66M | 240.31M | 251.68M |
Cash & Short-Term Investments | 42.05M | 112.63M | 75.55M | 133.79M | 102.43M | 121.97M | 72.45M | 71.62M | 111.04M | 111.75M |
Cash Only | 42.05M | 45.72M | 19.52M | 37.6M | 67.27M | 121.97M | 67.45M | 71.62M | 111.04M | 111.75M |
Short-Term Investments | 0 | 66.92M | 56.03M | 96.19M | 35.16M | 0 | 5M | 0 | 0 | 0 |
Accounts Receivable | 1.2M | 2.87M | 4.69M | 6.88M | 17.46M | 30.83M | 39.2M | 40.41M | 51.05M | 56.3M |
Days Sales Outstanding | 281.26 | 424.82 | 629.3 | 122.8 | 128.48 | 102.07 | 87.28 | 72.64 | 63.85 | 62.06 |
Inventory | 0 | 0 | 2.18M | 8.35M | 18.12M | 24.73M | 38.84M | 48.17M | 68.67M | 74.23M |
Days Inventory Outstanding | - | - | 495.47 | 326.85 | 496.55 | 398.88 | 494.88 | 477.41 | 469.29 | 437.06 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 9.29M | 5.78M | 7.45M | 9.55M | 9.4M |
Total Non-Current Assets | 945K | 2.13M | 21.5M | 6.94M | 161.76M | 157.7M | 166.34M | 155.4M | 143.21M | 140.33M |
Property, Plant & Equipment | 788K | 2.03M | 7.85M | 6.71M | 6.63M | 9.51M | 29.18M | 28.21M | 27.06M | 26.98M |
Fixed Asset Turnover | 1.97x | 1.21x | 0.35x | 3.05x | 7.48x | 11.60x | 5.62x | 7.20x | 10.79x | 11.56x |
Goodwill | 0 | 0 | 0 | 0 | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
Intangible Assets | 0 | 0 | 0 | 0 | 131.45M | 120.61M | 109.76M | 98.92M | 88.08M | 85.37M |
Long-Term Investments | 0 | 0 | 13.23M | 0 | 0 | 0 | 0 | 4.12M | 0 | 0 |
Other Non-Current Assets | 157K | 95K | 420K | 232K | 829K | 4.73M | 4.54M | -4.81M | 5.22M | 5.12M |
Total Assets | 45M▲ 0% | 120.03M▲ 166.7% | 108.99M▼ 9.2% | 159.15M▲ 46.0% | 304.36M▲ 91.2% | 344.52M▲ 13.2% | 322.6M▼ 6.4% | 323.06M▲ 0.1% | 383.53M▲ 18.7% | 392.01M▲ 0% |
Asset Turnover | 0.03x | 0.02x | 0.02x | 0.13x | 0.16x | 0.32x | 0.51x | 0.63x | 0.76x | 0.85x |
Asset Growth % | 34.19% | 166.74% | -9.2% | 46.03% | 91.24% | 13.2% | -6.36% | 0.14% | 18.72% | 59.16% |
Total Current Liabilities | 4.86M | 10.17M | 27.34M | 28.21M | 79.04M | 73.62M | 95.19M | 100.44M | 109.57M | 118.59M |
Accounts Payable | 1.98M | 866K | 5.6M | 3.12M | 8.92M | 4.61M | 11.56M | 2.29M | 3.08M | 11.47M |
Days Payables Outstanding | 180.31K | 7.53K | 1.28K | 121.97 | 244.58 | 74.28 | 147.36 | 22.69 | 21.02 | 48.06 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.1M | 6.23M | 6.27M |
Deferred Revenue (Current) | 234K | 232K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.3M | 4.98M | 9.06M | 11.2M | 25.63M | 27.23M | 51.43M | 39.75M | 100.27M | 100.86M |
Current Ratio | 9.06x | 11.59x | 3.20x | 5.40x | 1.80x | 2.54x | 1.64x | 1.67x | 2.19x | 2.12x |
Quick Ratio | 9.06x | 11.59x | 3.12x | 5.10x | 1.57x | 2.20x | 1.23x | 1.19x | 1.57x | 1.50x |
Cash Conversion Cycle | - | - | -151.02 | 327.68 | 380.46 | 426.67 | 434.8 | 527.36 | 512.11 | 451.06 |
Total Non-Current Liabilities | 97.97M | 34.45M | 67.21M | 97.18M | 130.09M | 225.71M | 234.19M | 252.23M | 260.26M | 260.41M |
Long-Term Debt | 0 | 31.89M | 58.3M | 87.02M | 88.07M | 187.07M | 190.93M | 217.01M | 31.53M | 31.06M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 9.4M | 34.76M | 33.26M | 0 | 32.44M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 4.94M | 3.52M | 2.27M | 0 | 0 | 0 |
Other Non-Current Liabilities | 97.97M | 2.56M | 8.91M | 10.16M | 37.08M | 25.72M | 6.23M | 1.97M | 228.73M | 229.35M |
Total Liabilities | 102.83M | 44.62M | 94.55M | 125.39M | 209.13M | 299.33M | 329.38M | 352.68M | 369.84M | 379M |
Total Debt | 0 | 31.89M | 58.3M | 87.02M | 88.07M | 198.06M | 229.19M | 271.45M | 37.76M | 37.33M |
Net Debt | -42.05M | -13.83M | 38.79M | 49.42M | 20.8M | 76.09M | 161.74M | 199.83M | -73.28M | -74.42M |
Debt / Equity | - | 0.42x | 4.04x | 2.58x | 0.92x | 4.38x | - | - | 2.76x | 2.87x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 1.02x | 0.77x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -1.98x | -1.53x |
Interest Coverage | -13277.00x | -22.61x | -16.60x | -10.95x | -16.09x | -5.81x | -1.39x | -0.80x | 0.02x | 1.13x |
Total Equity | -57.83M▲ 0% | 75.41M▲ 230.4% | 14.44M▼ 80.9% | 33.76M▲ 133.9% | 95.23M▲ 182.1% | 45.19M▼ 52.6% | -6.78M▼ 115.0% | -29.61M▼ 336.7% | 13.69M▲ 146.2% | 13.01M▲ 0% |
Equity Growth % | -81.09% | 230.39% | -80.86% | 133.87% | 182.07% | -52.55% | -115.01% | -336.67% | 146.22% | 380.13% |
Book Value per Share | -28.51 | 6.26 | 0.55 | 0.79 | 1.21 | 0.33 | -0.05 | -0.20 | 0.08 | 0.07 |
Total Shareholders' Equity | -57.83M | 75.41M | 14.44M | 33.76M | 95.23M | 45.19M | -6.78M | -29.61M | 13.69M | 13.01M |
Common Stock | 1K | 2K | 3K | 6K | 13K | 14K | 14K | 15K | 17K | 18K |
Retained Earnings | -60.59M | -120.67M | -246.25M | -337.38M | -460.11M | -554.77M | -617.02M | -671.86M | -671.31M | -669.07M |
Treasury Stock | -2.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -440K | -52K | 43K | 6K | -31K | -23K | -25K | -25K | -25K | -24K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XERS Cash Flow Statement
Xeris Biopharma Holdings, Inc. (XERS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -24.66M | -56.28M | -80.56M | -80.56M | -95.53M | -102.89M | -47.02M | -36.98M | 28.63M | 48.53M |
Operating CF Margin % | -1585.03% | -2283.12% | -2959.52% | -394.22% | -192.65% | -93.33% | -28.69% | -18.21% | 9.81% | - |
Operating CF Growth % | -53.31% | -128.19% | -43.14% | 0% | -18.59% | -7.7% | 54.3% | 21.36% | 177.41% | 1536.93% |
Net Income | -26.55M | -60.08M | -91.14M | -91.14M | -122.72M | -94.66M | -62.26M | -54.84M | 554K | 12.01M |
Depreciation & Amortization | 177K | 320K | 1.47M | 1.47M | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M | 12.31M |
Stock-Based Compensation | 499K | 1.73M | 6.48M | 8.27M | 11.38M | 12.16M | 10.72M | 18.36M | 22.37M | 17.92M |
Deferred Taxes | 0 | -414K | 536K | 1.11M | -1.42M | -1.42M | -1.25M | -2.27M | 0 | 0 |
Other Non-Cash Items | 94K | 560K | 4.89M | 39K | 3.5M | 3.52M | -1.1M | -2.04M | 3.91M | 8.01M |
Working Capital Changes | 1.12M | 1.61M | -2.8M | -312K | 11.85M | -35.15M | -6.29M | -8.82M | -10.36M | -1.72M |
Change in Receivables | -1.1M | -1.67M | -2.18M | -6.24M | -13.37M | -13.37M | -8.37M | -1.22M | -10.63M | -9.96M |
Change in Inventory | 1.7M | 4.04M | -5.14M | -7.42M | -7.46M | -7.46M | -14.8M | -8.78M | -19.29M | -14.82M |
Change in Payables | 661K | -1.11M | -2.49M | 5.53M | -4.32M | -4.32M | 6.96M | -9.61M | -69K | 119K |
Cash from Investing | -700K | -68.26M | -27.41M | -27.41M | 34.46M | 34.46M | -6M | 4.88M | -696K | -1.01M |
Capital Expenditures | -700K | -1.51M | -377K | -377K | -524K | -524K | -2.26M | -868K | -696K | -1.3M |
CapEx % of Revenue | 44.99% | 61.26% | 13.85% | 1.84% | 1.06% | 0.48% | 1.38% | 0.43% | 0.24% | 0.41% |
Acquisitions | 0 | 0 | 377K | 0 | 38.47M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -66.75M | -377K | 0 | 4.55M | 0 | 0 | 0 | 0 | 292K |
Cash from Financing | 35.14M | 128.21M | 126.06M | 126.06M | 27.25M | 127.47M | -1.61M | 36.17M | 11.39M | 5.69M |
Debt Issued (Net) | 0 | 35M | 25M | 69.75M | 0 | 102.72M | 0 | 38.17M | 9.17M | 9.17M |
Equity Issued (Net) | 35.48M | 93.54M | 0 | 65.83M | 27.25M | 29.53M | -1.01M | -3.73M | 2.22M | -3.48M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -63K | -534K | -468K | -1.01M | -3.73M | -10.88M | -19.89M |
Other Financing | -336K | -333K | 101.06M | -9.51M | 0 | -4.78M | -604K | 1.73M | 0 | 0 |
Net Change in Cash | 9.78M▲ 0% | 3.67M▼ 62.4% | 18.08M▲ 392.5% | 29.67M▲ 64.1% | 59.04M▲ 99.0% | 59.04M▲ 0.0% | -54.64M▼ 192.5% | 4.07M▲ 107.4% | 39.32M▲ 866.1% | 53.21M▲ 0% |
Free Cash Flow | -25.36M▲ 0% | -57.79M▼ 127.8% | -80.94M▼ 40.1% | -96.62M▼ 19.4% | -103.42M▼ 7.0% | -103.42M▲ 0.0% | -49.29M▲ 52.3% | -37.85M▲ 23.2% | 27.93M▲ 173.8% | 47.23M▲ 0% |
FCF Margin % | -1630.01% | -2344.38% | -2973.37% | -472.82% | -208.54% | -93.8% | -30.07% | -18.64% | 9.57% | 15% |
FCF Growth % | -57.32% | -127.85% | -40.05% | -19.38% | -7.03% | 0% | 52.34% | 23.21% | 173.79% | 272.2% |
FCF per Share | -12.51 | -4.80 | -3.10 | -2.27 | -1.31 | -0.76 | -0.36 | -0.26 | 0.16 | 0.27 |
FCF Conversion (FCF/Net Income) | 0.93x | 0.94x | 0.64x | 0.88x | 0.78x | 1.09x | 0.76x | 0.67x | 51.67x | 3.93x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.95M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XERS Key Ratios
Xeris Biopharma Holdings, Inc. (XERS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -683.66% | -279.56% | -378.2% | -190.28% | -134.83% | -324.2% | - | 4.05% | 735% |
Return on Invested Capital (ROIC) | - | - | -159.9% | -91.87% | -86.71% | -51.79% | -23.9% | -15.52% | 33.76% | 3205.54% |
Gross Margin | 99.74% | 98.3% | 41.11% | 54.35% | 73.14% | 79.47% | 82.52% | 81.86% | 81.7% | 81.59% |
Net Margin | -1706.56% | -2437.32% | -4613.52% | -446% | -247.48% | -85.86% | -37.98% | -27% | 0.19% | 3.81% |
Debt / Equity | - | 0.42x | 4.04x | 2.58x | 0.92x | 4.38x | - | - | 2.76x | 2.87x |
Interest Coverage | -13277.00x | -22.61x | -16.60x | -10.95x | -16.09x | -5.81x | -1.39x | -0.80x | 0.02x | 1.13x |
FCF Conversion | 0.93x | 0.94x | 0.64x | 0.88x | 0.78x | 1.09x | 0.76x | 0.67x | 51.67x | 3.93x |
Revenue Growth | 44.74% | 58.42% | 10.43% | 650.73% | 142.67% | 122.32% | 48.68% | 23.89% | 43.72% | 41.47% |
Related:XERS Dividend History·XERS Revenue History·XERS Price History·XERS P/E History·XERS Financial Ratios·XERS Institutional Holders
XERS SEC Filings & Documents
Xeris Biopharma Holdings, Inc. (XERS) SEC filings — annual & quarterly reports (10-K, 10-Q)
XERS Frequently Asked Questions
Xeris Biopharma Holdings, Inc. (XERS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Xeris Biopharma Holdings, Inc. (XERS) reported $314.9M in revenue for fiscal year 2025. This represents a 29189% increase from $1.1M in 2016.
Xeris Biopharma Holdings, Inc. (XERS) grew revenue by 43.7% over the past year. This is strong growth.
Yes, Xeris Biopharma Holdings, Inc. (XERS) is profitable, generating $12.0M in net income for fiscal year 2025 (0.2% net margin).
Dividend & Returns
Xeris Biopharma Holdings, Inc. (XERS) has a return on equity (ROE) of 4.0%. This is below average, suggesting room for improvement.
Xeris Biopharma Holdings, Inc. (XERS) generated $47.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.